Christoph Lengauer

44.9k citations

129 papers · 31.7k indexed · 20 hit papers · h-index 66

Cancer Research top 0.05%
- Cancer Genomics and Diagnostics 26
Oncology top 0.05%
- Cancer-related Molecular Pathways 19
Cell Biology top 0.05%
- Microtubule and mitosis dynamics 26
Molecular Biology top 0.05%
- DNA Repair Mechanisms 18
- PI3K/AKT/mTOR signaling in cancer 11
Pathology and Forensic Medicine top 0.05%
- Genetic factors in colorectal cancer 27
Genetics
- Genomic variations and chromosomal abnormalities 24
Plant Science
- Chromosomal and Genetic Variations 17

Co-authors: Bert Vogelstein Kenneth W. Kinzler Harith Rajagopalan Victor E. Velculescu Todd Waldman Fred Bunz Sanford D. Markowitz James K. V. Willson
Cited by: Cancer Research Oncology Cell Biology
Journals: Nature (13 papers)Science (5 papers)Cell (1 paper)
Partner nations: United States Germany Austria

In The Last Decade

Christoph Lengauer

128 papers receiving 31.0k citations

Hit Papers

15 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2015 Journal of Clinical Investigation
2014 Nature Communications
2009 Science
2005 Cancer Cell
2004 Nature
2002 Nature
2002 Nature
2001 Science
2000 Science
1999 Nature
1999 Trends in Cell Biology
1999 Journal of Clinical Investigation
1998 Nature
1998 Nature
1998 Science
1998 Nature Genetics
1997 Molecular Cell
1997 Nature
1996 Nature Genetics
1996 Nature

Peers

Countries citing papers authored by Christoph Lengauer

Since Specialization

Citations

This map shows the geographic impact of Christoph Lengauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Lengauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Lengauer more than expected).

Fields of papers citing papers by Christoph Lengauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Lengauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Lengauer. The network helps show where Christoph Lengauer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Christoph Lengauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christoph Lengauer Line = papers co-authored together Christoph Lengauer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis Leukemia ·Johannes Lübke,Nicole Naumann,Sebastian Kluger,Juliana Schwaab,Georgia Metzgeroth,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Wolf‐Karsten Hofmann,Alice Fabarius,Nicholas C.P. Cross,Andreas Reiter,Mohamad Jawhar	2019	33
2	Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors Clinical Cancer Research ·Yemarshet K. Gebreyohannes,Agnieszka Woźniak,Madalina-Elena Zhai,Jasmien Wellens,Jasmien Cornillie,Ulla Vanleeuw,Erica N Evans,Alexandra K. Gardino,Christoph Lengauer,Maria Dêbiec‐Rychter,Raf Sciot,Patrick Schöffski	2018	57
3	Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/ BRAF -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor Molecular Cancer Therapeutics ·Hélène Bonnevaux,Olivier Lemaitre,Loı̈c Vincent,Mikhail Levit,Fanny Windenberger,Frank Halley,Cécile Delorme,Christoph Lengauer,Carlos Garcı́a-Echeverrı́a,Angéla Virone-Oddos	2016	17
4	First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway Cancer Discovery ·Margit Hagel,Chandra Miduturu,Michael P. Sheets,Nooreen Rubin,Weifan Weng,Nicolas Stransky,Neil Bifulco,Joseph L. Kim,Brian L. Hodous,Natasja Brooijmans,Adam Shutes,Christopher Winter,Christoph Lengauer,Nancy E. Kohl,Timothy J. Guzi	2015	247
5	Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors Bioorganic & Medicinal Chemistry Letters ·Victor Certal,Frank Halley,Angéla Virone-Oddos,Bruno Filoche-Rommé,Jean‐Christophe Carry,Florence Gruss-Leleu,Luc Bertin,Houlfa Guizani,Fabienne Pilorge,Patrick Richepin,Andreas Karlsson,Véronique Charrier,Pierre-Yves Abecassis,Loı̈c Vincent,Jean-Paul Nicolas,Christoph Lengauer,Carlos Garcı́a-Echeverrı́a,Laurent Schio	2014	5
6	The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells Cancer Research ·Zainab Jagani,Dmitri Wiederschain,Alice Loo,Dan He,Rebecca Mosher,Paul Fordjour,John E. Monahan,Michael Morrissey,Yung-Mae Yao,Christoph Lengauer,Markus Warmuth,William R. Sellers,Marion Dorsch	2010	48
7	Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cellsbreakdown → Science ·Jihye Yun,Carlo Rago,Ian Cheong,Ray Pagliarini,Philipp Angenendt,Harith Rajagopalan,Kerstin Schmidt,James K. V. Willson,Sandy D. Markowitz,Shibin Zhou,Luis A. Díaz,Victor E. Velculescu,Christoph Lengauer,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos	2009	724
8	Crystal structure of human CDK4 in complex with a D-type cyclin Proceedings of the National Academy of Sciences ·Philip J. Day,Anne Cleasby,Ian J. Tickle,Marc O’Reilly,Joe E. Coyle,Finn P. Holding,Rachel McMenamin,Jeff Yon,Rajiv Chopra,Christoph Lengauer,Harren Jhoti	2009	176
9	PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers Cancer Research ·Susan Wee,Zainab Jagani,Kay X. Xiang,Alice Loo,Marion Dorsch,Yung‐Mae Yao,William R. Sellers,Christoph Lengauer,Frank Stegmeier	2009	354
10	Single-vector inducible lentiviral RNAi system for oncology target validation Cell Cycle ·Dmitri Wiederschain,W Nicolson Susan,Lin Chen,Alice Loo,Guizhi Yang,Alan Huang,Yan Chen,Giordano Caponigro,Yung-Mae Yao,Christoph Lengauer,William R. Sellers,John D. Benson	2009	306
11	PTEN-deficient cancers depend on PIK3CB Proceedings of the National Academy of Sciences ·Susan Wee,Dmitri Wiederschain,Sauveur-Michel Maira,Alice Loo,Christine Miller,Rosalie deBeaumont,Frank Stegmeier,Yung-Mae Yao,Christoph Lengauer	2008	411
12	Mutant PIK3CA promotes cell growth and invasion of human cancer cellsbreakdown → Cancer Cell ·Yardena Samuels,Luis A. Díaz,Oleg Schmidt‐Kittler,Jordan M. Cummins,Laura J. DeLong,Ian Cheong,Carlo Rago,David L. Huso,Christoph Lengauer,Kenneth W. Kinzler,Bert Vogelstein,Victor E. Velculescu	2005	727
13	CIN-ful cancers Cancer Chemotherapy and Pharmacology ·Harith Rajagopalan,Christoph Lengauer	2004	18
14	Cloning and chromosomal localization of the human BARX2 homeobox protein gene Gene ·Alan Krasner,Lalena Wallace,Arunthathi Thiagalingam,Christopher T. Jones,Christoph Lengauer,Lara Minahan,Yongkang Ma,Linda M. Kalikin,Andrew P. Feinberg,Ethylin Wang Jabs,Alan Tunnacliffe,Stephen B. Baylin,Douglas W. Ball,Barry D. Nelkin	2000	20
15	Conversion of diploidy to haploidy Nature ·Hai Yan,Nickolas Papadopoulos,Giancarlo Marra,Claudia Perrera,Josef Jiricny,C. Richard Boland,Henry T. Lynch,Robert B. Chadwick,Albert de la Chapelle,Karin Berg,James R. Eshleman,Weishi Yuan,Sanford D. Markowitz,Steven J. Laken,Christoph Lengauer,K W Kinzler,Bert Vogelstein	2000	200
16	Genetic instabilities in human cancersbreakdown → Nature ·Christoph Lengauer,Kenneth W. Kinzler,Bert Vogelstein	1998	3228
17	Characterization of Human FAST-1, a TGFβ and Activin Signal Transducer Molecular Cell ·Shibin Zhou,Leigh Zawel,Christoph Lengauer,K. W. Kinzler,Bert Vogelstein	1998	208
18	Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancersbreakdown → Nature Genetics ·Sam Thiagalingam,Christoph Lengauer,Frederick S. Leach,Mieke Schutte,Stephan A. Hahn,Joan Overhauser,James K. V. Willson,Sanford D. Markowitz,Stanley R. Hamilton,Scott E. Kern,K W Kinzler,Bert Vogelstein	1996	501
19	Painting of defined chromosomal regions by in situ suppression hybridization of libraries from laser-microdissected chromosomes Cytogenetic and Genome Research ·Christoph Lengauer,A. Eckelt,Andreas Weith,Nicole Endlich,Norbert Ponelies,Peter Lichter,Karl‐Otto Greulich,Thomas Cremer	1991	35
20	Painting of human chromosomes with probes generated from hybrid cell lines by PCR with Alu and L1 primers Human Genetics ·Christoph Lengauer,Harold Riethman,Thomas Cremer	1990	53

About Christoph Lengauer

Christoph Lengauer is a scholar working on Cancer Research, Pathology and Forensic Medicine and Cell Biology, having authored 129 papers that have together received 31.7k indexed citations. Recurring topics across this work include Genetic factors in colorectal cancer (27 papers), Microtubule and mitosis dynamics (26 papers), Cancer Genomics and Diagnostics (26 papers), Genomic variations and chromosomal abnormalities (24 papers), Cancer-related Molecular Pathways (19 papers), DNA Repair Mechanisms (18 papers), Chromosomal and Genetic Variations (17 papers) and PI3K/AKT/mTOR signaling in cancer (11 papers). The work is most often cited by research in Cancer Research (7.4k citations), Oncology (11.7k citations) and Cell Biology (5.7k citations). Christoph Lengauer has collaborated with scholars based in United States, Germany and Austria. Frequent co-authors include Bert Vogelstein, Kenneth W. Kinzler, Harith Rajagopalan, Victor E. Velculescu, Todd Waldman, Fred Bunz, Sanford D. Markowitz, James K. V. Willson, Carlo Rago and Daniel P. Cahill. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact